Company news
Arecor Therapeutics PLC news in 2025
Arecor Therapeutics PLC's news releases, calls and decks from 2025, newest first.
Arecor and Sequel Med Tech to host fireside panel
December 9, 2025
Holding(s) in Company
November 17, 2025
Enhanced IP Coverage: AT278 & Oral Peptide Program
November 4, 2025
Directorate Changes
September 29, 2025
Arecor announces Co-development Agreement with US Insulin Pump Device Company for AT278 & Sale of Royalty Rights and Technology Access Fees for AT220 and AT292
September 25, 2025
Interim results for the six months to 30 June 2025
September 25, 2025
Co-Development Agreement & Monetisation Deal
September 25, 2025
Notice of Interim Results
September 24, 2025
Positive FDA Feedback on Phase 2 Study Design
September 4, 2025
Change of Auditor
August 8, 2025
Arecor Establishes New Scientific Advisory Board
July 14, 2025
Grant of Options and PDMR Dealing
June 4, 2025
Result of AGM
June 2, 2025
Non-Executive Director Board Change
June 2, 2025
Director/PDMR Dealing
May 21, 2025
Arecor Partnership with Skye Bioscience
May 19, 2025
Director Dealing
May 14, 2025
Arecor sells rights to non-Ogluo® products
May 8, 2025
Posting of 2024 Annual Report and Notice of AGM
May 6, 2025
Arecor to present on Investor Meet Company
April 24, 2025
Final results for 2024
April 22, 2025
Notice of Results
April 10, 2025
Collaboration with global pharmaceutical partner
March 26, 2025
Arecor partnership with biopharmaceutical company
March 12, 2025
Arecor Full Year 2024 Trading Update
February 3, 2025
Orderly Cessation of Tetris Pharma Operations
January 10, 2025
Change of Nominated Advisor and Joint Broker
January 9, 2025
Calls in 2025
Decks in 2025
- FY2024 Earnings Presentation
Earnings · 21 slides · Apr 22, 2025